Research Analysts’ Weekly Ratings Changes for CRISPR Therapeutics (CRSP)

A number of firms have modified their ratings and price targets on shares of CRISPR Therapeutics (NASDAQ: CRSP) recently:

• 6/27/2026 – CRISPR Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/13/2026 – CRISPR Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/12/2026 – CRISPR Therapeutics was given a new $80.00 price target by UBS Group AG.
• 6/11/2026 – CRISPR Therapeutics was given a new $60.00 price target by Morgan Stanley. They now have an “equal weight” rating on the stock.
• 5/27/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/13/2026 – CRISPR Therapeutics had its price target raised by Sanford C. Bernstein from $50.00 to $56.00. They now have a “market perform” rating on the stock.
• 5/11/2026 – CRISPR Therapeutics had its “outperform” rating reaffirmed by Evercore Inc. They now have a $76.00 price target on the stock.
• 5/9/2026 – CRISPR Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/6/2026 – CRISPR Therapeutics had its price target raised by Citigroup Inc. from $80.00 to $82.00. They now have a “buy” rating on the stock.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the sale, the insider directly owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.